JP2008546403A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546403A5
JP2008546403A5 JP2008517701A JP2008517701A JP2008546403A5 JP 2008546403 A5 JP2008546403 A5 JP 2008546403A5 JP 2008517701 A JP2008517701 A JP 2008517701A JP 2008517701 A JP2008517701 A JP 2008517701A JP 2008546403 A5 JP2008546403 A5 JP 2008546403A5
Authority
JP
Japan
Prior art keywords
marker
allele
tcf7l2
markers
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008517701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546403A (ja
JP5301987B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IS2006/000014 external-priority patent/WO2006137085A1/en
Publication of JP2008546403A publication Critical patent/JP2008546403A/ja
Publication of JP2008546403A5 publication Critical patent/JP2008546403A5/ja
Application granted granted Critical
Publication of JP5301987B2 publication Critical patent/JP5301987B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008517701A 2005-06-20 2006-06-16 ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体 Expired - Fee Related JP5301987B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69217405P 2005-06-20 2005-06-20
US60/692,174 2005-06-20
US75715506P 2006-01-06 2006-01-06
US60/757,155 2006-01-06
PCT/IS2006/000014 WO2006137085A1 (en) 2005-06-20 2006-06-16 Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Publications (3)

Publication Number Publication Date
JP2008546403A JP2008546403A (ja) 2008-12-25
JP2008546403A5 true JP2008546403A5 (enExample) 2009-08-06
JP5301987B2 JP5301987B2 (ja) 2013-09-25

Family

ID=37036993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517701A Expired - Fee Related JP5301987B2 (ja) 2005-06-20 2006-06-16 ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体

Country Status (14)

Country Link
US (3) US7585630B2 (enExample)
EP (1) EP1907569B1 (enExample)
JP (1) JP5301987B2 (enExample)
KR (1) KR101374304B1 (enExample)
CN (1) CN101238222B (enExample)
AU (1) AU2006260477B2 (enExample)
BR (1) BRPI0612301A2 (enExample)
CA (1) CA2612475C (enExample)
EA (1) EA016397B1 (enExample)
IL (1) IL188147A (enExample)
MX (1) MX2007015848A (enExample)
NO (1) NO341910B1 (enExample)
NZ (1) NZ564285A (enExample)
WO (1) WO2006137085A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006137085A1 (en) * 2005-06-20 2006-12-28 Decode Genetics Ehf. Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2099937A2 (en) * 2006-11-30 2009-09-16 Decode Genetics EHF Genetic susceptibility variants of type 2 diabetes mellitus
US20080287650A1 (en) * 2007-03-01 2008-11-20 Avi Tovi High purity peptides
WO2008132744A2 (en) * 2007-04-30 2008-11-06 Compugen Ltd. Allelic polymorphism associated with diabetes
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010269841A1 (en) * 2009-07-10 2012-02-23 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus
NZ599298A (en) * 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2971163A4 (en) * 2013-03-14 2017-03-22 The Children's Hospital of Philadelphia Tcf7l2 variant and methods of use thereof in diagnostic and drug screening assays
RU2521202C1 (ru) * 2013-04-12 2014-06-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ прогнозирования риска развития сахарного диабета второго типа у больных гипертонической болезнью
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN103882127B (zh) * 2014-03-13 2016-03-16 河北联合大学 用于预测患2型糖尿病肾病发生风险的试剂盒
WO2016201438A1 (en) * 2015-06-11 2016-12-15 The Children's Hospital Of Philadelphia New targets modulated by a casual variant of type 2 diabetes (t2d) embedded within the tcf7l2 gene and methods of use thereof for identifying agents having efficacy for the treatment of type 2 diabetes and other metabolic disorders
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN109182508A (zh) * 2018-10-22 2019-01-11 北京华夏时代生物工程有限公司 Tcf7l2基因单核苷酸多态性的荧光原位杂交测序方法
TWI702292B (zh) * 2018-12-28 2020-08-21 薩摩亞商康多富國際有限公司 個人化新陳代謝疾病保健食品組合的決定方法及非暫態電腦可讀取儲存媒體

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
DE3486488T2 (de) * 1983-01-10 2003-04-03 Gen-Probe Inc., San Diego Verfahren zum Nachweis, Identifizieren und Quantifizieren von Organismen und Viren
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3534934A1 (de) * 1985-10-01 1987-04-02 Draegerwerk Ag Kolorimetrisches gasdosimeter
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6417185B1 (en) * 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
PT1237880E (pt) * 1999-12-17 2008-03-05 Novartis Vaccines & Diagnostic Inibidores baseados em pirazina da cinase 3 da glicogénio sintase
CN100335479C (zh) * 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
ATE450604T1 (de) * 2000-07-27 2009-12-15 Novartis Vaccines & Diagnostic Gsk3-polypeptide
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
AU2002324649A1 (en) * 2001-08-04 2003-02-24 General Hospital Corporation Haplotype map of the human genome and uses therefor
WO2003024447A1 (en) 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
JP2006506988A (ja) * 2002-11-01 2006-03-02 デコード ジェネティクス イーエッチエフ． 染色体５ｑ３５に位置したヒトＩＩ型糖尿病遺伝子−ＳＬＩＴ−３
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
CN1548553A (zh) * 2003-05-21 2004-11-24 中国医学科学院基础医学研究所 用于预测2型糖尿病易感性的试剂盒及引物
US6991110B2 (en) * 2003-07-02 2006-01-31 Inficon, Inc. Package for storing sensor crystals and related method of use
RU2383547C2 (ru) * 2003-08-28 2010-03-10 Чоонгвае Фарма Корпорейшн Модуляция бета-катенин/tcf-активируемой транскрипции
WO2006137085A1 (en) * 2005-06-20 2006-12-28 Decode Genetics Ehf. Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Similar Documents

Publication Publication Date Title
CN107475371B (zh) 发现药物基因组生物标志物的方法
Takata et al. A population-specific uncommon variant in GRIN3A associated with schizophrenia
JP2010507388A5 (enExample)
JP2011530306A5 (enExample)
JP2014533949A5 (enExample)
JP2007529714A5 (enExample)
JP2009526524A5 (enExample)
JP2010520745A5 (enExample)
JP2012503985A5 (enExample)
JP2010533477A5 (enExample)
JP2008537474A5 (enExample)
JP2013544536A5 (enExample)
JP2011528903A5 (enExample)
JP2009544314A5 (enExample)
JP2008509673A5 (enExample)
NZ598009A (en) Genetic markers associated with risk of diabetes mellitus
CN104232781A (zh) 一种检测HLA-B*5801等位基因的TaqMan探针实时荧光PCR方法
Chinault et al. Application of dual-genome oligonucleotidearray-based comparative genomic hybridization to the molecular diagnosis of mitochondrial DNA deletion and depletion syndromes
EP3332031A1 (en) Snp rs12603226 as a predictive marker for nafld
JP2010510804A5 (enExample)
JP4140329B2 (ja) 高血圧のリスク診断方法
KR20150070042A (ko) Hla-b*1301 대립유전자의 용도
US10939868B2 (en) Method of predicting rapid progression of fibrosis and therapy and reagents therefor
JP2012507291A5 (enExample)
CN106834501A (zh) 与中国儿童肥胖相关的单核苷酸多态性位点及其应用